Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 9.50 INR
Change Today -0.40 / -4.04%
Volume 97.3K
PDL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

parabolic drugs ltd (PDL) Snapshot

Open
9.40
Previous Close
9.90
Day High
10.00
Day Low
9.40
52 Week High
09/16/14 - 18.20
52 Week Low
03/16/15 - 6.90
Market Cap
588.0M
Average Volume 10 Days
66.1K
EPS TTM
-61.47
Shares Outstanding
61.9M
EX-Date
09/24/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PARABOLIC DRUGS LTD (PDL)

Related News

No related news articles were found.

parabolic drugs ltd (PDL) Related Businessweek News

No Related Businessweek News Found

parabolic drugs ltd (PDL) Details

Parabolic Drugs Limited develops and manufactures active pharmaceutical ingredients (API) and API intermediates. The company offers oral and sterile semi synthetic penicillin APIs; and oral and sterile cephalosporin APIs in antibiotic area, as well as non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company markets its products in approximately 50 countries, primarily including the Middle East, the United Kingdom, Africa, China, Korea, Japan, the European Union, Latin America, the United States, and ASEAN. Parabolic Drugs Limited was founded in 1996 and is headquartered in Chandigarh, India.

1,011 Employees
Last Reported Date: 07/20/10
Founded in 1996

parabolic drugs ltd (PDL) Top Compensated Officers

Chairman, Managing Director and Member of Aud...
Total Annual Compensation: 12.4M
Whole-Time Director
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2014.

parabolic drugs ltd (PDL) Key Developments

Parabolic Drugs Ltd. Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015 and Consolidated Earnings Results for the Year Ended March 31, 2015

Parabolic Drugs Ltd. announced audited standalone earnings results for the fourth quarter and year ended March 31, 2015 and consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 266.1 million against INR 1,120.5 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 923.3 million against INR 941.1 million a year ago. Loss from ordinary activities before tax was INR 1,352.2 million against INR 1,176.6 million a year ago. Net loss was INR 2,885.9 million or INR 46.63 per basic and diluted share before & after extraordinary items against INR 610.1 million or INR 9.86 per basic and diluted share before & after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 2,287.8 million against INR 4,303.8 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 1,503.1 million against INR 1,369.5 million a year ago. Loss from ordinary activities before tax was INR 2,490.0 million against INR 2,200.2 million a year ago. Net loss was INR 3,793.2 million or INR 61.29 per basic and diluted share before & after extraordinary items against INR 1,317.4 million or INR 21.29 per basic and diluted share before & after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 2,403.0 million against INR 4,467.0 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 1,511.6 million against INR 1,383.9 million a year ago. Loss from ordinary activities before tax was INR 2,501.5 million against INR 2,220.9 million a year ago. Net loss was INR 3,804.7 million or INR 61.48 per basic and diluted share before & after extraordinary items against INR 1,338.1 million or INR 21.62 per basic and diluted share before & after extraordinary items a year ago.

Parabolic Drugs Ltd., Board Meeting, May 18, 2015

Parabolic Drugs Ltd., Board Meeting, May 18, 2015. Agenda: To consider and approve the audited financial results for the quarter and the year ended on March 31, 2015.

Parabolic Drugs Ltd. to Report Q4, 2015 Results on May 18, 2015

Parabolic Drugs Ltd. announced that they will report Q4, 2015 results on May 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDL:IN 9.50 INR -0.40

PDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDL.
View Industry Companies
 

Industry Analysis

PDL

Industry Average

Valuation PDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARABOLIC DRUGS LTD, please visit www.parabolicdrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.